We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Novel Noninvasive Diagnostic Test Developed for Colorectal Cancer

By LabMedica International staff writers
Posted on 15 Mar 2015
Print article
Image: Microscopic image of circulating tumor cells captured by IBN’s liquid biopsy microsieve (Photo courtesy of Institute of Bioengineering and Nanotechnology).
Image: Microscopic image of circulating tumor cells captured by IBN’s liquid biopsy microsieve (Photo courtesy of Institute of Bioengineering and Nanotechnology).
Image: To develop a liquid biopsy for metastasized cancer, researchers designed a silicon microsieve with a densely packed array of pores to rapidly capture circulating tumor cells from whole blood (Photo courtesy of Institute of Bioengineering and Nanotechnology).
Image: To develop a liquid biopsy for metastasized cancer, researchers designed a silicon microsieve with a densely packed array of pores to rapidly capture circulating tumor cells from whole blood (Photo courtesy of Institute of Bioengineering and Nanotechnology).
Researchers have developed a genetic test for colorectal cancer (CRC) using a novel liquid “biopsy” of circulating tumor cells (CTCs) from whole blood, a rapid, easy-to-use technology developed to improve treatment, monitoring, and overall care of cancer patients.

The CTC liquid biopsy and CRC genetic test were developed by researchers from the Institute of Bioengineering and Nanotechnology (IBN; Singapore) of Singapore’s Agency for Science, Technology and Research (A*STAR). The standard approach tests surgically removed tissue for genotyping. If the cancer has metastasized, additional samples are removed, which comes with additional pain, inconvenience, risk of acquired infection, and financial costs. In contrast, IBN’s liquid biopsy enables testing blood samples, offering a relatively non-invasive alternative.

“We are excited about our liquid biopsy approach, which could make it easier for doctors to check and administer the appropriate drug treatment for cancer patients. Our technologies have been validated by Fortis Surgical Hospital and have been successfully licensed for clinical applications,” said Prof. Jackie Y. Ying, executive director, IBN.

CTCs provide early indication of metastasis, but are extremely rare. IBN researchers fabricated a silicon microsieve to rapidly capture and enrich CTCs from blood. Measuring 7.5 mm in diameter, the microsieve utilizes a densely packed array of 90,000 fine pores to separate CTCs (generally larger and stiffer) from normal blood cells, within 5 minutes. IBN’s microsieve can be used for rapid detection and clinical analysis of CTCs and for metastasis research.

CRC is known to have two key mutated genes, KRAS and BRAF. IBN researchers developed ultrasensitive molecular assays to identify mutations using the CTCs. The assays, tested on 44 CRC surgery patients, were highly accurate in detecting KRAS and BRAF mutations, a major milestone of the Fortis-IBN TissueBank, established to advance translational research in colorectal care.

Dr. Min-Han Tan, IBN team leader and principal research scientist, said: “Our work shows matching genetic mutations in the tumor tissue and corresponding CTCs of patients with CRC. This opens up an avenue for liquid biopsies, or the testing of cancer cells through blood, which we hope can reduce the need for invasive biopsies.”

The noninvasive genetic test was recently licensed to AITbiotech Pte Ltd. (Singapore) for development into a ready-to-use kit. “We are pleased to be IBN’s commercialization partner for these test kits. This is a good example of a win-win public-private partnership, whereby a local SME like us is able to leverage on IBN’s expertise,” said AITbiotech CEO Alex Thian. The microsieve technology was licensed in 2011 to CellSievo Pte Ltd (of IBN) for commercialization.

Dr. Poh-Koon Koh, senior consultant and director, Colorectal Surgical Oncology & Cancer Genetics Service, Fortis Surgical Hospital, and IBN adjunct clinician scientist, said: “In partnering IBN to set up the Fortis-IBN TissueBank, our aim was to create a resource that will allow cutting-edge research to benefit patients clinically. This liquid biopsy invention is an invaluable tool [and] allows a noninvasive means to obtain DNA material in tumors that are not easily or safely accessible through conventional biopsy techniques.”

The noninvasive genetic test for colorectal cancer was reported by Mohd Suhaimi NA et al., online January 2015, in the journal Molecular Oncology. The microsieve capture of CTCs from whole blood was reported by Lim LS et al., online August 2012, in the journal Lab on a chip.

Related Links:

Institute of Bioengineering and Nanotechnology
Agency for Science, Technology and Research (A*STAR)


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.